Odelle Technology ’s Post

🌟 **Oncology Molecular Diagnostic Market Insight** 🌟 The Oncology Molecular Diagnostic Market was valued at US$ 3.36 Bn in 2021 and is projected to reach USD 9.37 Bn by 2029, exhibiting a CAGR of 13.68% during the forecast period from 2022 to 2029. ### Oncology Molecular Diagnostic Market Overview: Oncology molecular diagnostics involve the analysis of biological chemicals in cancer cells to detect their presence. These diagnostics use several assays to identify and measure specific genetic sequences in DNA, RNA, and cell proteins from samples such as blood, saliva, and tumor tissue. This technology aids in rapid analysis and provides specific information that helps tailor cancer treatment to individuals. Key Applications: - **Clinical and Point-of-Care (POC) Tests**: For early cancer detection. - **Blood Banks**: To detect infections and infectious diseases in donated blood. ### Market Growth Drivers: - **Rapid Analysis**: The need for quick and precise diagnostic information. - **Personalized Treatment**: Increasing demand for individualized cancer treatment plans. - **Early Detection**: Rising importance of early cancer diagnosis to improve treatment outcomes. - **Infection Detection**: Utilization in blood banks to ensure the safety of blood donations. ### Future Prospects: The oncology molecular diagnostics market is poised for significant growth due to advancements in diagnostic technologies and an increasing focus on personalized medicine. The market's expansion is also driven by the growing importance of early cancer detection and the need for safe blood transfusion practices. #OncologyDiagnostics #MolecularDiagnostics #CancerDetection #PersonalizedMedicine #MarketGrowth #MedicalInnovation #HealthcareAdvancement #EarlyDetection #BloodSafety Click Here:https://lnkd.in/gGQM9NXd Oncology Molecular Diagnostic Market Key Players are: • Abbott Laboratories • Bayer Healthcare AG • Beckman Coulter Diagnostics Coulter, Inc. • Becton Dickinson Company (Safety Syringes, Inc. ), Dickinson and Company

A Complete Guide of Oncology Based Molecular Diagnostics Market Get Free Sample Copy of This Research Report: ( https://lnkd.in/g_nktXKc )   Oncology-based molecular diagnostics entails the utilization of molecular biology techniques to detect, diagnose, and monitor cancer by analyzing the genetic, molecular, and biochemical features of cancer cells. This process provides valuable insights into tumor development, progression, and treatment response. Point-of-care testing (POCT) refers to medical diagnostic testing conducted outside the traditional laboratory setting, often in close proximity to the patient. In oncology, there is a rising demand for POCT to expedite swift and precise diagnosis, facilitate treatment monitoring, and streamline disease management processes.   In 2023, North America held a significant market share of 40.6% in the oncology based molecular diagnostics market and is predicted to witness substantial market growth over the analysis timeline. The high prevalence of cancer in North America fuels demand for early and accurate diagnostics, while a growing emphasis on personalized medicine promotes adoption of molecular diagnostics.   Growth Drivers: 1. Increasing prevalence of cancer worldwide 2. Technological advancements in molecular diagnostics 3. Growing demand for personalized medicine 4. Rising demand for point-of-care testing

Labcorp's most recent research, presented at the 2024 SGO Annual Meeting, highlights the crucial role of biomarker testing in guiding personalized treatments for epithelial ovarian cancer. Genomic profiling is transforming patient care, ensuring better patient outcomes through tailored therapies #precisionmedicine #cancerdiagnostics #biotouch https://hubs.li/Q02pYm3c0

Engage in Lifescience - Engage in Talent - Engage in Health #oncology #cancertreatment #cartcell #clinicalresearch #pharmaceutical #precisiononcology #cancerawareness

Developments in Oncology Our Life Sciences team recognises the critical role oncology plays in diagnosing, treating, and managing cancer, a leading global cause of mortality. Through discussions with medical professionals, academics, and industry leaders, we understand that advancements in this field significantly impact patient survival and quality of life. CAR T-cell Therapy: One noteworthy area of development is CAR T-cell therapy. This innovative treatment involves modifying a patient’s T-cells to specifically target and destroy cancer cells. We have been actively researching this therapy, learning about the intricate processes of cell collection, genetic modification, and gene expression from leading scientists in the field. While our engagement provides only a glimpse into this cutting-edge research, we are proud to connect with experts advancing new therapies to improve and extend patients' lives worldwide. If your team needs expertise in oncology—whether medical, clinical, commercial, or research-related—please contact us at: engage@engagegroup.com.sg or lifescience@engagegroup.com.sg We're here to help. Engage Lifescience (Singapore & South East Asia) #oncology #cancertreatment #cartcell #clinicalresearch #pharmaceutical #precisiononcology #cancerawareness Please feel free to connect to our team members below: Florence Wong f.wong@engagegroup.com.sg Corey Lo MPH c.lo@engagegroup.com.sg Resources: https://lnkd.in/g6akdKU4

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications. We are excited to announce dosing of the first patient in our first-in-human study of BBI-825, our second program to enter the clinic, said Klaus Wagner M.D., Ph.D., Chief Medical Officer at Boundless Bio. BBI-825 represents a new approach in the potential treatment of oncogene amplifications, particularly in resistance associated with targeted therapy treatment of MAPK pathway-activated cancers. STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is an open-label, non-randomized, three-part Phase 1/2 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamic biomarkers, preliminary antitumor activity, and identify the maximum tolerated dose and recommended Phase 2 dose (RP2D) of BBI 825 administered as a single agent or in combination with select targeted therapies (NCT06299761). Part 1 is a dose escalation of BBI-825 as a monotherapy in patients with solid tumors. Part 2 is a combination dose escalation of BBI-825 and targeted therapies, encorafenib and cetuximab, or adagrasib and cetuximab, in patients with advanced or metastatic colorectal cancer with BRAFV600E or KRASG12C mutations, respectively, and co-occurring resistance gene amplifications. Part 3 is a combination dose expansion to evaluate preliminary anti-tumor activity at the RP2D of BBI-825 and each targeted therapy combination from Part 2. #oncology #oncologyresearch #clinicalresearch #clinicaltrials

Engage in Lifescience - Engage in Talent - Engage in Health #oncology #cancertreatment #cartcell #clinicalresearch #pharmaceutical #precisiononcology #cancerawareness

In case you missed the work published by Mary K Nesline et al. last week published in Oncology and Therapy... The Labcorp Oncology medical affairs team examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC). “Our findings have significant implications for patients with NSCLC...Undertesting and incomplete testing for oncogenic driver mutations can lead not only to underutilization of frontline targeted therapy, but also to improper use of upfront immune checkpoint inhibitors in patients with actionable genomic variants who can derive clinically meaningful benefits from biomarker-driven targeted therapy.” Bottomline: CGP should be performed on every advanced and metastatic NSCLC tumor. Want to read more? https://lnkd.in/eQebDqeS Vivek Subbiah, MD Kyle Strickland Heidi Ko, DO Paul DePietro Maureen Cooper Nini Wu, MD Jeffrey Conroy Sarabjot Pabla Zachary Wallen, PhD Pratheesh Sathyan PhD Kamal S. Saini Marcia Eisenberg Brian Caveney Eric Severson Shakti Ramkissoon

Precision Oncology is a cutting-edge approach to cancer treatment, customizing therapies based on individual characteristics of each patient's disease for enhanced efficiency and reduced toxicity. BioServe Biotechnologies is committed to delivering a comprehensive molecular diagnostic solution for Oncology, encompassing hereditary risk assessment, differential diagnosis, reliable prognosis, targeted treatment selection, therapy monitoring, and disease surveillance. Genetic testing plays a crucial role in predicting cancer risk by identifying subtle alterations in genes, chromosomes, or proteins. These alterations, known as "mutations," provide valuable insights into an individual's predisposition to developing cancer. To know more click here https://lnkd.in/d3NcnYcX To know More About Our Range of Services: Website: [www.bioserve.in] Contact Form: [https://lnkd.in/duuytdzr] To Call: +91 912 122 9283 Email: bioserve.india@reprocell.com Social Media Platforms: Instagram: https://lnkd.in/gz4Bm7hw YouTube: https://lnkd.in/gDXT5d3K Twitter:https://lnkd.in/gRSKYP8R Facebook: https://lnkd.in/gBEJrq3c #PrecisionOncologyTreatment #PersonalizedCancerCare #TargetedTherapies #PrecisionMedicine #CancerTreatmentOptions #PrecisionOncologyAdvancements #PrecisionCareApproach #EffectiveCancerTherapies #TailoredCancerTreatment #InnovationsInOncology #bioserve #reprocell #hereditarycancer #genetictesting #cancerscreening

#cancerresearch #oncology #cancertreatment #breastcancer https://lnkd.in/gymyGDMG Abstract Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical outcomes. Relentless research efforts in #molecular #biology and drug development have led to the implementation of several HER2-targeted therapies, including monoclonal #antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, constituting one of the best examples of bench-to-bedside translation in oncology. Each individual drug class has improved patient outcomes and, importantly, the combinatorial and sequential use of different HER2-targeted therapies has increased cure rates in the early stage disease setting and substantially prolonged survival for patients with advanced-stage disease. In this Review, we describe key steps in the development of the modern paradigm for the treatment of HER2-positive advanced-stage breast cancer, including selecting and sequencing new-generation HER2-targeted therapies, and summarize efficacy and safety outcomes from pivotal studies. We then outline the factors that are currently known to be related to resistance to HER2-targeted therapies, such as HER2 intratumoural heterogeneity, activation of alternative signalling pathways and immune escape mechanisms, as well as potential strategies that might be used in the future to overcome this resistance and further improve patient outcomes.